These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34263067)

  • 21. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
    Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
    Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    Shen W; Middleton MS; Cunha GM; Delgado TI; Wolfson T; Gamst A; Fowler KJ; Alazraki A; Trout AT; Ohliger MA; Shah SN; Bashir MR; Kleiner DE; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Zhou J; Sirlin CB; Lavine JE
    J Hepatol; 2023 Feb; 78(2):238-246. PubMed ID: 36368598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis.
    Ismaiel A; Leucuta DC; Popa SL; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
    Panminerva Med; 2021 Dec; 63(4):508-518. PubMed ID: 33165307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
    Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
    World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis: analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis.
    Ng CH; Muthiah MD; Xiao J; Chin YH; Lim G; Lim WH; Tay P; Tan DJH; Yong JN; Pan XH; Koh JWH; Chew N; Syn N; Tan E; Huang DQ; Siddiqui MS; Loomba R; Sanyal AJ; Noureddin M
    Aliment Pharmacol Ther; 2022 May; 55(9):1076-1087. PubMed ID: 35285529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
    Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
    PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
    Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients.
    Canivet CM; Zheng MH; Qadri S; Vonghia L; Chuah KH; Costentin C; George J; Armandi A; Adams LA; Lange NF; Blanchet O; Moal V; Younes R; Roux M; Chan WK; Sturm N; Eslam M; Bugianesi E; Wang Z; Dufour JF; Francque S; Yki-Järvinen H; Zheng KI; Boursier J
    Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3097-3106.e10. PubMed ID: 37031715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
    Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A
    Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis.
    Pennisi G; Celsa C; Enea M; Vaccaro M; Di Marco V; Ciccioli C; Infantino G; La Mantia C; Parisi S; Vernuccio F; Craxì A; Cammà C; Petta S
    Nutr Metab Cardiovasc Dis; 2022 Oct; 32(10):2279-2288. PubMed ID: 35970684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of histologic, imaging, and artificial intelligence features in NAFLD patients, derived from Gd-EOB-DTPA-enhanced MRI: a proof-of-concept study.
    Bastati N; Perkonigg M; Sobotka D; Poetter-Lang S; Fragner R; Beer A; Messner A; Watzenboeck M; Pochepnia S; Kittinger J; Herold A; Kristic A; Hodge JC; Traussnig S; Trauner M; Ba-Ssalamah A; Langs G
    Eur Radiol; 2023 Nov; 33(11):7729-7743. PubMed ID: 37358613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
    Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
    Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
    Stine JG; Munaganuru N; Barnard A; Wang JL; Kaulback K; Argo CK; Singh S; Fowler KJ; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2274-2283.e5. PubMed ID: 32882428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis.
    Koutoukidis DA; Jebb SA; Tomlinson JW; Cobbold JF; Aveyard P
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e538-e547. PubMed ID: 33813074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 40. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.
    Newton KP; Lavine JE; Wilson L; Behling C; Vos MB; Molleston JP; Rosenthal P; Miloh T; Fishbein MH; Jain AK; Murray KF; Schwimmer JB;
    Hepatology; 2021 Mar; 73(3):937-951. PubMed ID: 32416645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.